Rep. Waxman to revisit Rx drug pricing
Executive Summary
The House Commerce/Health Subcommittee chairman is considering a second round of hearings on pharmaceutical industry price hikes. At a hearing last summer, the California Democrat criticized the industry for continued double-digit Rx drug price inflation, despite patent restoration and R&E tax credits, when general inflation was running below 4% ("The Pink Sheet" July 22, 1985, p. 5). If Waxman holds another hearing, he is expected to ask HHS Assistant Secretary for Planning & Evaluation Robert Helms to return as a witness. The chairman is reportedly concerned that after three years of review and comments on how to reform Rx drug reimbursement under Medicaid, HHS only recently published a proposal on MAC that included three disparate alternatives ("The Pink Sheet" Aug. 25, p. 3).
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.